Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
4.8 USD -4.19% Intraday chart for 2seventy bio, Inc. +9.59% +12.41%
May. 08 Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M MT
May. 08 Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
BU
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
AQ
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
BU
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma
AQ
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy
AQ
2seventy bio : Corporate Presentation April 2024
PU
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
BU
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
BU
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?
PR
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
AQ
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
BU
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
AQ
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
BU
2seventy bio to Participate in Upcoming Investor Conferences
BU
2seventy bio Announces New Strategic Path Forward
BU
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
BU
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
BU
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
AQ
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
BU
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. News 2seventy bio, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW